Navigation Links
Lakewood-Amedex Inc. Receives Notice of Allowance on Three US Patent Applications Relating to Treatment of Hemolytic Uremic Syndrome
Date:1/27/2011

SARASOTA, Fla., Jan. 27, 2011 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that the United States Patent and Trademark Office has issued Notice of Allowances on three patent applications relating to the use of novel monoclonal antibodies for the treatment of hemolytic uremic syndrome (HUS) caused by shiga toxin II secreting E.coli O157: H7 strain.

Lakewood Amedex is the exclusive licensee of the US patents, issued to Tufts University.  Based on work led by Saul Tzipori, BVSc., DSc., PhD, distinguished professor of biomedical sciences at the Cummings School of Veterinary Medicine at Tufts, as well as other members of the school's Division of Infectious Diseases, the patents entitled -- "Humanized Neutralizing Antibodies against Hemolytic Uremic Syndrome" -- are the first patents to be granted in this family and will provide the Company with a strong intellectual property position for treating this serious illness.  HUS is usually associated with E.coli 0157:H7 food poisoning and affects more than 300,000 people worldwide annually.  There is currently no approved therapeutics for the treatment of this condition, which mainly affects young children and the elderly, as well as individuals with compromised immune systems.  The Company is seeking to fast-track development of its lead fully human monoclonal antibody candidate into clinical trials in 2011.

The Company's head scientist, Paul DiTullio, commented "The granting of these three patents will give Lakewood-Amedex a dominant position for the use of monoclonal antibodies to treat this life threatening condition.  Although the initial indication will be for the treatment of hemolytic uremic syndrome, the Company believes the product will have a more expanded usage in preventing the kidney damage caused by shiga toxin in patients suffering from a less severe infection which can lead to a number of health complications later in life.  The market for this product is estimated to be between $100 million and $400 million annually on a worldwide basis.

About Lakewood-Amedex, Inc.

Lakewood-Amedex is a privately held biopharmaceutical company developing a broad portfolio of anti-infective products, including first-in-class anti-bacterial compounds, orally available nanoRNA therapeutics for acute and chronic diseases such as arthritis, inflammation, influenza, and hepatitis, and a fully human monoclonal antibody for HUS.  The Company's products and technology are covered by an extensive patent portfolio consisting of 27 granted and/or issued patents and 32 pending patent applications filed on a worldwide basis covering all major pharmaceutical markets.  The Company's lead therapeutic candidate is a novel synthetic broad spectrum anti-bacterial proven to be effective in killing a wide range of gram positive, gram negative, and antibiotic-resistant bacteria and is expected to enter the clinic in 2011.

This press release contains forward-looking statements that can be identified by terminology such as "expects", "potential", "suggests", "may", "will" or similar expressions.  Such forward-looking statements regarding our business, which are not historical facts, are "forward-looking statements" that involve risk and uncertainties, which could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements.  Actual results may differ materially from statements made as a result of various factors, including, but not limited to sufficiency of cash to fund the Company's operations, risk associated with product research and development, and competition.  Forward-looking statements speak only as to the date they are made.  The Company does not undertake to update forward-looking statements to reflect the circumstances or events that occur after the date the forward-looking statements are made.Contacts:Steve ParkinsonPresident and CEOLakewood-Amedex Inc.(941) 255 2515sparkinson@lakewoodamedex.com
'/>"/>

SOURCE Lakewood-Amedex Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lakewood-Amedex Inc. to Develop Broad Spectrum Influenza Drug to Include H1N1 and H5N1 Type A Strains
2. Varian Medical Systems Security and Inspection Products Group Receives Largest Single Order for IntellX Systems
3. Crestwood Technology Group Receives Silver Boeing Performance Excellence Award
4. HeartWare Receives Third Patient Allotment From FDA - Authorizing 94 Additional Patients - Under Continued Access Protocol for Pivotal U.S. Bridge-to-Transplant Clinical Trial
5. Mylans Matrix Receives Approval for Generic Version of Protonix® Delayed-release Tablets
6. Aribex CEO Receives Utah Governors Medal
7. Mylans Matrix Receives Tentative FDA Approval Under PEPFAR for Lamivudine and Zidovudine Tablets, 30 mg/60 mg
8. Mindray Receives its Largest Order of Patients Monitors in Canada
9. ADVENTRX Pharmaceuticals Receives PDUFA Date for Exelbine™ NDA
10. Zyga Technology, Inc. Receives FDA 510(K) Clearance for the SImmetry™ Sacroiliac Joint Fusion System
11. Cambrex Zenara Manufacturing Facility Receives European GMP Approval
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... Research and Markets has announced the addition of the ... to 2021" report to their offering. ... , , The immunohistochemistry (IHC) ... a CAGR of 7.3% during the forecast period of 2016 to 2021. ... rapidly increasing geriatric population across the globe are the primary driving the ...
(Date:12/7/2016)... 7, 2016  Palatin Technologies, Inc. ("Palatin") (NYSE ... a previously disclosed underwritten public offering of units ... as sole book-running manager, Roth Capital Partners acted ... as co-manager for the offering. "This ... net proceeds, allowing us to continue advancing bremelanotide ...
(Date:12/7/2016)... , Dec. 7, 2016 DelveInsight,s, ... report provides in depth insights on the ... the Janus Kinase 3 (JAK3) Inhibitors. The ... various stages of development including Discovery, Pre-clinical, ... and Preregistration. Report covers the product clinical ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... When it came time to blow out his candles on ... later, the Pediatric Heart Transplant team at Joe DiMaggio Children’s Hospital surprised his ... the hospital’s 30th heart transplant recipient. , “He was playing at home, when we ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... financial consultation services to residents in the Sacramento/Folsom region, is initiating a charity ... facility. , The Another Choice Another Chance treatment center in Sacramento works to ...
(Date:12/7/2016)... , ... December 07, 2016 , ... AlignLife clinics nationwide ... Many children are not fortunate enough to receive bountiful gifts wrapped tightly under a ... can bring to the children of the world. , In exchange for generous donations, ...
(Date:12/7/2016)... OR (PRWEB) , ... December 07, 2016 , ... Sharon ... Water, Global Climate Change and Your Health on Voice of America, declared on her ... to call attention to the fact that when these bullies attack leaders in corporate ...
(Date:12/7/2016)... ... December 07, 2016 , ... Delete® - Tattoo Removal and Laser Salon Offers ... Season. Save Up To 33% Off Botox® and Juvederm® Products Now Through December 31, ... with Delightful Deals on Botox® and Juvederm® just in time for the ...
Breaking Medicine News(10 mins):